High pre-chemoradiotherapy pan-immune-inflammation value levels predict worse outcomes in patients with stage IIIB/C non-small-cell lung cancer
Abstract Background and objectives We explored the prognostic usefulness of the pan-immune-inflammation value (PIV) in patients with stage IIIB/C non-small-cell lung cancer (NSCLC) who underwent concurrent chemoradiotherapy (CCRT). Methods and patients For all patients, the PIV was calculated using...
Main Authors: | , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Springer
2023-12-01
|
Series: | Discover Oncology |
Subjects: | |
Online Access: | https://doi.org/10.1007/s12672-023-00851-8 |